Aflibercept biosimilar is under clinical development by Alvotech and currently in Phase III for Choroidal Neovascularization. According to GlobalData, Phase III drugs for Choroidal Neovascularization have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Aflibercept biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Aflibercept biosimilar overview

Aflibercept biosimilar (AVT06) is under development for the treatment of neovascular (wet) age-related macular degeneration. The drug candidate acts by targeting placenta growth factor (PGF) and vascular endothelial growth factor A, B (VEGF-A and VEGF-B). It is administered in the form of intravitreal injection.

Alvotech overview

Alvotech is a biopharmaceutical company that focuses on the development and manufacturing of biosimilar medicines. The company’s purpose is to improve the health and quality of life of patients by improving access to proven treatments for various diseases. Its current pipeline contains eight biosimilar candidates for the treatment of autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. The company also offers research and development services. It has operations in Luxemburg, Switzerland, Germany, Australia and Iceland. Alvotech is headquartered in Luxemburg.

For a complete picture of Aflibercept biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.